Antibody targeting of cathepsin s inhibits angiogenesis and synergistically enhances anti-VEGF

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Ward, Claire ^a   Kuehn, Diana ^a   Burden, Roberta E ^a,b   Gormley, Julie A ^a   Jaquin, Thomas J ^a   Gazdoiu, Mihaela ^a   Small, Donna ^a,b   Bicknell, Roy ^c   Johnston, James A ^b   Scott, Christopher J ^b   Olwill, Shane A ^a  

^a FUSION ANTIBODIES LTD   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; FN 0503; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; ANTIBODY; CATHEPSIN; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL INVASION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; IMMUNOLOGY; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; CATHEPSINS; CELL LINE; DOWN-REGULATION; DRUG SYNERGISM; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958603409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012543     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
2. Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395-404.
3. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, et al. (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res.60: 5565-70.
4. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, et al. (2002) PTK787/ ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-22.
5. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-9.
6. Chen HX, Cleck JN (2008) Antiangiogenic clinical strategies: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009; 6: 465-77.
7. Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: Role of myeloid cells. Cancer Res 68: 5501-5504.
8. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15: 220-231.
9. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, et al. (1999) Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 10: 207-17.
10. Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, et al. (1999) Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 10: 197-206.
11. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, et al. (2003) Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 92: 493-500.
12. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, et al. (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281: 6020-9.
13. Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, et al. (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66: 198-211.
14. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, et al. (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-56.
15. Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, et al. (2009) Antibody-mediated inhibition of Cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15: 6042-6051.
16. Ades EW, Cadal FJ, Swerlick RA, George VG, Summers S, et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. Invest Dermatol 99(6): pp 683-90.
17. Burden RE, Snoddy P, Buick RJ, Johnston JA, Walker B, et al. (2008) Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol Cancer Ther 7: 538-47.
18. Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R (2005) Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer 92: 1696-701.
19. Bergsland E, Dickler MN (2004) Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9 Suppl 1: 36-42.
20. Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, et al. (1997) Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119: 227-35.
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350: 2335-42.
22. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, et al. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-21.
23. Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15: 167-70.
24. Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6: 764-75.
25. Jordans S, Jenko-Kokalj S, Kuhl NM, Tedelind S, Sendt W, et al. (2009) Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem 22: 10-23.
26. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce J (2007) Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 67: 7378-85.